Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease | Zendy

Marc P. Bonaca | Zendy; Patrice Nault | Zendy; Robert P. Giugliano | Zendy; Anthony Keech | Zendy; Armando Lira Pineda | Zendy; Estella Kanevsky | Zendy; Julia Kuder | Zendy; Sabina A. Murphy | Zendy; J. Wouter Jukema | Zendy; Basil S. Lewis | Zendy; Lâle Tokgözoğlu | Zendy; Ransi Somaratne | Zendy; Peter Sever | Zendy; Terje R. Pedersen | Zendy; Marc S. Sabatine | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Author(s) -

Marc P. Bonaca,

Patrice Nault,

Robert P. Giugliano,

Anthony Keech,

Armando Lira Pineda,

Estella Kanevsky,

Julia Kuder,

Sabina A. Murphy,

J. Wouter Jukema,

Basil S. Lewis,

Lâle Tokgözoğlu,

Ransi Somaratne,

Peter Sever,

Terje R. Pedersen,

Marc S. Sabatine

Publication year - 2017

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.117.032235

Subject(s) - medicine , evolocumab , arterial disease , peripheral , cardiology , cholesterol , disease , pcsk9 , lipoprotein , atherosclerotic cardiovascular disease , vascular disease , ldl receptor , apolipoprotein a1

The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on major adverse limb events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research